Adult T-Cell Leukemia Clinical Trials

Find Adult T-Cell Leukemia Clinical Trials Near You

A Phase 2, Multicenter, Single-arm, Open-label Study on the Efficacy and Safety of PI3K Inhibitors in Relapsed/Refractory Large Granular T Lymphocytic Leukemia

Status: Recruiting
Location: See all (3) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

This is a prospective, multicenter, single-arm, phase 2 study. This study aims to evaluate the efficacy and safety of Linperlisib, the PI3K delta inhibitor for patients with relapsed/refractory large granular T lymphocytic leukemia.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Male or female age ≥ 18 years

• Diagnosis of T-cell large granular lymphocytic leukemia (T-LGLL)

• Meet any of the following indications for treatment: 1. Hemoglobin \< 100g/L or RBC transfusion dependence 2. Neutrophil count \<0.5×10\^9/L or neutrophil count decreased with recurrent infection 3. Progressive splenomegaly and/or Massive Splenomegaly 4. Combined with autoimmune diseases requiring treatment, such as rheumatoid arthritis, autoimmune thyroiditis, etc. 5. Severe B symptoms

• Failure or intolerance to a first-line therapy

• ECOG performance status ≤2

• Expected survival ≥ 6 months

• Willing and able to comply with the requirements for this study and written informed consent

Locations
Other Locations
China
Anhui Provincial Hospital
RECRUITING
Hefei
Regenerative Medicine Center
RECRUITING
Tianjin
Zhoukou Central Hospital
RECRUITING
Zhoukou
Contact Information
Primary
Jun Shi, PhD
shijun@ihcams.ac.cn
13752253515
Backup
Lele Zhang, PhD
zhanglele@ihcams.ac.cn
15811139278
Time Frame
Start Date: 2023-12-03
Estimated Completion Date: 2026-01-31
Participants
Target number of participants: 41
Treatments
Experimental: Linperlisib
Linperlisib was administered at 80 mg every day, orally in a 28-day cycle until disease progression or intolerable toxicity occurred.
Related Therapeutic Areas
Sponsors
Collaborators: YL-Pharma
Leads: Institute of Hematology & Blood Diseases Hospital, China

This content was sourced from clinicaltrials.gov

Similar Clinical Trials